• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

促黄体生成素释放激素(LHRH)激动剂醋酸布舍瑞林对睾酮处理的去势大鼠腹侧前列腺上皮细胞增殖的增强作用。

Potentiating effect of buserelin acetate, an LHRH agonist, on the proliferation of ventral prostatic epithelial cells in testosterone-treated castrated rats.

作者信息

Maezawa H, Komatsu H, Kawaoi A, Ueno A

机构信息

Department of Urology, Yamanashi Medical University, Nakakoma-gun, Japan.

出版信息

Int J Urol. 1997 Jul;4(4):411-6. doi: 10.1111/j.1442-2042.1997.tb00217.x.

DOI:10.1111/j.1442-2042.1997.tb00217.x
PMID:9256333
Abstract

BACKGROUND

We used buserelin acetate ([D-Ser(But)6] LHRH ), an LHRH agonist and strong blocker of LH secretion, as a treatment for prostatic cancer. It is possible that this LHRH agonist has a proliferative effect on the prostate in addition to suppressing LH secretion. The purpose of this study was to examine the proliferative effect of LHRH agonist on rat prostatic epithelial cells.

METHODS

We determined the optimal dose of testosterone necessary to maintain a positive level of proliferating cell nuclear antigen (PCNA) in the ventral prostatic epithelial cells of castrated Wistar rats. Testosterone-treated rats then received various doses of buserelin acetate. Castrated rats without exogenous testosterone also received buserelin acetate. The PCNA positivity was determined by immunohistochemistry with anti-PCNA monoclonal antibody.

RESULTS

The optimal dose of testosterone enanthate was 4 mg at 0 and 28 days after castration. Administration of buserelin acetate on day 0 and 28 in doses of 0.16 mg to 1.28 mg significantly increased PCNA positivity in a dose-dependent manner. Administration of buserelin acetate to castrated rats without testosterone also increased PCNA positivity but there was no statistical significance.

CONCLUSIONS

Buserelin acetate has a potentiating effect on the proliferation of ventral prostatic epithelial cells of castrated rat in the presence of a physiological level of exogenous testosterone. This effect may slightly influence the result of hormonal therapy by LHRH agonist.

摘要

背景

我们使用醋酸布舍瑞林([D-丝氨酸(叔丁基)6]促黄体激素释放激素),一种促黄体激素释放激素激动剂和促黄体生成素分泌的强效阻滞剂,作为前列腺癌的治疗药物。除抑制促黄体生成素分泌外,这种促黄体激素释放激素激动剂可能对前列腺有增殖作用。本研究的目的是检测促黄体激素释放激素激动剂对大鼠前列腺上皮细胞的增殖作用。

方法

我们确定了维持去势Wistar大鼠腹侧前列腺上皮细胞增殖细胞核抗原(PCNA)阳性水平所需的睾酮最佳剂量。然后,用睾酮处理的大鼠接受不同剂量的醋酸布舍瑞林。未接受外源性睾酮的去势大鼠也接受醋酸布舍瑞林。通过抗PCNA单克隆抗体免疫组织化学法测定PCNA阳性率。

结果

在去势后0天和28天,庚酸睾酮的最佳剂量为4mg。在第0天和第28天给予0.16mg至1.28mg剂量的醋酸布舍瑞林可显著增加PCNA阳性率,且呈剂量依赖性。对未接受睾酮的去势大鼠给予醋酸布舍瑞林也可增加PCNA阳性率,但无统计学意义。

结论

在存在生理水平外源性睾酮的情况下,醋酸布舍瑞林对去势大鼠腹侧前列腺上皮细胞的增殖有增强作用。这种作用可能会对促黄体激素释放激素激动剂的激素治疗结果产生轻微影响。

相似文献

1
Potentiating effect of buserelin acetate, an LHRH agonist, on the proliferation of ventral prostatic epithelial cells in testosterone-treated castrated rats.促黄体生成素释放激素(LHRH)激动剂醋酸布舍瑞林对睾酮处理的去势大鼠腹侧前列腺上皮细胞增殖的增强作用。
Int J Urol. 1997 Jul;4(4):411-6. doi: 10.1111/j.1442-2042.1997.tb00217.x.
2
Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.大鼠前列腺重量对酮康唑、醋酸环丙孕酮和RU 23908的反应回归,作为促性腺激素释放激素类似物长效制剂的辅助药物。
Cancer Res. 1988 Nov 1;48(21):6063-8.
3
Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns.使用促黄体生成素释放激素(LHRH)激动剂避孕:对促性腺激素和类固醇分泌模式的影响。
Clin Endocrinol (Oxf). 1984 Aug;21(2):179-88. doi: 10.1111/j.1365-2265.1984.tb03458.x.
4
Synergistic effect of testosterone and of a luteinizing hormone-releasing hormone agonist on androgen receptor content in the ventral prostate of castrated rats.睾酮与促黄体生成素释放激素激动剂对去势大鼠腹侧前列腺雄激素受体含量的协同作用。
Steroids. 1989 Jan-Feb;53(1-2):195-217. doi: 10.1016/0039-128x(89)90153-0.
5
Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.接受前列腺癌长期药物去势治疗的男性在促黄体生成素释放激素激动剂治疗停止后激素恢复的个体差异。
Scand J Urol Nephrol. 2006;40(3):198-203. doi: 10.1080/00365590600641533.
6
Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma.
Prostate. 1983;4(6):601-24. doi: 10.1002/pros.2990040607.
7
[New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].前列腺癌治疗的新方法:促黄体生成素释放激素(LHRH)激动剂与雄激素拮抗剂联合使用
J Pharmacol. 1983;14 Suppl 3:117-35.
8
Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.前列腺癌患者黄体生成素释放激素激动剂治疗停止后激素反应的前瞻性测定。
Urology. 1999 May;53(5):898-902; discussion 902-3. doi: 10.1016/s0090-4295(99)00061-8.
9
Inhibition of testicular androgen biosynthesis by chronic administration of a potent LHRH agonist in adult men.成年男性长期施用强效促黄体生成素释放激素(LHRH)激动剂对睾丸雄激素生物合成的抑制作用。
Arch Androl. 1985;14(2-3):95-106. doi: 10.3109/01485018508988284.
10
Relationship between release of LH and incorporation of tritiated thymidine in the anterior pituitary gland of the castrated male rat: effect of LHRH and its highly active analogue buserelin.去势雄性大鼠垂体前叶中促黄体生成素释放与氚标记胸腺嘧啶核苷掺入之间的关系:促性腺激素释放激素及其高活性类似物布舍瑞林的作用
Horm Metab Res. 1986 Jan;18(1):31-3. doi: 10.1055/s-2007-1012218.